CSIMarket Company Name, Ticker, Competitors, else..
 
Ginkgo Bioworks Holdings Inc   (NYSE: DNA)
Other Ticker:  
 
 
Price: $7.2700 $-0.11 -1.491%
Day's High: $7.3226 Week Perf: -7.62 %
Day's Low: $ 6.91 30 Day Perf: 9.32 %
Volume (M): 435 52 Wk High: $ 41.20
Volume (M$): $ 3,165 52 Wk Avg: $11.93
Open: $7.14 52 Wk Low: $5.00



 Market Capitalization (Millions $) 377
 Shares Outstanding (Millions) 52
 Employees 400
 Revenues (TTM) (Millions $) 227
 Net Income (TTM) (Millions $) -547
 Cash Flow (TTM) (Millions $) -384
 Capital Exp. (TTM) (Millions $) 63

Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks Holdings Inc is a biotechnology company based in the United States. It specializes in synthetic biology and genetic engineering to design and manufacture organisms for various applications. The company's primary focus is on the fields of pharmaceuticals, agriculture, and industrial chemicals. Ginkgo Bioworks utilizes its unique platform to develop custom microbes that can produce high-value molecules and materials efficiently. They have collaborated with numerous companies to enhance their production processes and create new products. Ginkgo Bioworks has gained significant attention and investment in recent years for its innovative approach to bioengineering and its potential to revolutionize various industries.


   Company Address: 27 Drydock Avenue Boston 2210 MA
   Company Phone Number: 422-5362   Stock Exchange / Ticker: NYSE DNA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        3.96% 
BEAM   -0.81%    
CRSP   -2.96%    
EDIT   -4.97%    
EXEL        4.81% 
KRYS        2.88% 
• View Complete Report
   



Business Update

Syngenta and Ginkgo Bioworks Unite Forces to Unleash Revolutionary Agricultural Biotechnology

Published Tue, Jul 16 2024 12:36 PM UTC

Syngenta and Ginkgo Bioworks Join Forces to Revolutionize Agricultural BiotechnologyBASEL, Switzerland & BOSTON - Syngenta Crop Protection, a global leader in agricultural innovation, has partnered with Ginkgo Bioworks, a pioneering company specializing in cell programming and biosecurity, to accelerate the launch of a groundbreaking biological solution. This collaboration m...
Contract

Advancing Ice-Control Proteins: Ginkgo Bioworks Receives DARPA Funding for Novel Solutions in Extreme Cold Environments

Published Thu, Mar 28 2024 11:02 AM UTC

Abstract:This article examines the recent announcement by Ginkgo Bioworks, a leading company in cell programming and biosecurity, regarding its successful acquisition of a contract worth up to $6 million from the Defense Advanced Research Projects Agency (DARPA). The funding will be utilized by Ginkgo Bioworks to develop novel proteins intended to regulate ice formation in ...
Product Service News

bit.bio joins Ginkgo Bioworks' Technology Network to Uphold Cell Therapy and Drive Innovation in Biotechnology IndustryARTICLE:CAMBRIDGE, England & BOSTON - In a major development for the biotechnology industry, bit.bio, the pioneering company specializing in coding human cells for groundbreaking therapeutics, has been announced as an inaugural partner of the Ginkgo Technology Network...

Published Wed, Feb 28 2024 12:12 PM UTC

NEWS HEADLINE:bit.bio joins Ginkgo Bioworks Technology Network to Revolutionize Cell Therapy and Drive Innovation in Biotechnology IndustryARTICLE:CAMBRIDGE, England & BOSTON - In a major development for the biotechnology industry, bit.bio, the pioneering company specializing in coding human cells for groundbreaking therapeutics, has been announced as an inaugural partner o...
Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks Holdings Inc Fights Back: Battling Weak Sales, Generating Excitement in the Financial Third Quarter of 2023



Ginkgo Bioworks Holdings Inc, a leading biotechnology and pharmaceuticals company, recently released its financial report for the third quarter of 2023. The report highlights several key financial indicators, including revenues, net shortfall, inventory levels, and accounts receivable. Let's delve deeper into these figures to understand the company's performance during the quarter.
Decreased Losses per Share:
Ginkgo Bioworks Holdings Inc experienced a significant improvement in its financial performance during the third quarter of 2023. The company reported a loss per share of $-0.16, compared to $-0.41 in the same quarter the previous year. This reduction in losses indicates that the company has taken steps to control costs and improve its bottom line. Additionally, when compared to the preceding quarter, the loss per share narrowed even further from $-0.09.






Ginkgo Bioworks Holdings Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com